API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com/news-release/2024/04/15/2862775/0/en/Reviva-Announces-FDA-Alignment-on-Brilaroxazine-Clinical-Trials-for-NDA-in-Schizophrenia.html
https://www.globenewswire.com/news-release/2024/03/28/2853940/0/en/Reviva-to-Present-RECOVER-Phase-3-Clinical-Trial-Data-for-Brilaroxazine-in-Schizophrenia-at-the-SIRS-2024-Annual-Meeting.html
https://www.globenewswire.com//news-release/2024/02/06/2824256/0/en/Reviva-to-Host-KOL-Event-to-Discuss-Topline-Data-from-Phase-3-RECOVER-Trial-of-Brilaroxazine-in-Schizophrenia.html
https://health.economictimes.indiatimes.com/news/pharma/reviva-pharmas-schizophrenia-drug-succeeds-in-late-stage-study/104835266
https://www.globenewswire.com//news-release/2023/09/25/2748446/0/en/Reviva-Announces-Last-Patient-Evaluated-in-Pivotal-Phase-3-RECOVER-Trial-for-Brilaroxazine-in-Schizophrenia.html
https://www.globenewswire.com//news-release/2023/08/17/2727043/0/en/Reviva-Announces-Enrollment-Completion-for-Pivotal-Phase-3-RECOVER-Study-for-Brilaroxazine-in-Schizophrenia.html
https://www.globenewswire.com/news-release/2023/06/22/2692705/0/en/Reviva-Pharmaceuticals-Announces-80-Global-Enrollment-Update-for-Pivotal-Phase-3-RECOVER-Study-Evaluating-Brilaroxazine-for-Schizophrenia.html
https://www.globenewswire.com/news-release/2023/05/22/2673186/0/en/Reviva-Pharmaceuticals-Announces-Presentation-of-Clinical-Pharmacology-Studies-Data-on-Brilaroxazine-at-the-ASPET-2023-Annual-Meeting.html
https://www.globenewswire.com/news-release/2023/05/11/2666465/0/en/Reviva-Pharmaceuticals-Announces-Intent-to-File-an-IND-for-Brilaroxazine-in-Psoriasis-After-Promising-Preclinical-Data.html
https://www.globenewswire.com/news-release/2023/05/01/2658572/0/en/Reviva-Pharmaceuticals-Presented-Foundational-Preclinical-Data-on-Novel-Serotonin-Dopamine-Stabilizer-Brilaroxazine-at-the-78th-Annual-SOBP-and-Publication-in-Medical-Research-Arch.html
https://www.globenewswire.com/news-release/2023/04/25/2653710/0/en/Reviva-Pharmaceuticals-to-Host-Key-Opinion-Leader-Event-on-Brilaroxazine-RP5063-in-Phase-3-Clinical-Trials-for-Schizophrenia.html
https://www.globenewswire.com/news-release/2023/04/20/2651560/0/en/Reviva-Pharmaceuticals-to-Present-on-Novel-Serotonin-Dopamine-Stabilizer-Brilaroxazine-at-the-78th-Annual-Scientific-Convention-of-the-Society-of-Biological-Psychiatry.html
https://www.globenewswire.com/news-release/2022/10/31/2544512/0/en/Reviva-Pharmaceuticals-Announces-Global-Enrollment-Update-for-Pivotal-Phase-3-RECOVER-Study-Evaluating-Brilaroxazine-for-Schizophrenia.html
https://www.globenewswire.com/news-release/2022/08/15/2498581/0/en/Reviva-Pharmaceuticals-Holdings-Inc-Reports-Second-Quarter-2022-Financial-Results-and-Recent-Business-Highlights.html
https://www.globenewswire.com/news-release/2022/04/26/2428824/0/en/Reviva-Pharmaceuticals-to-Host-Key-Opinion-Leader-Webinar-on-Brilaroxazine-for-Schizophrenia-and-Other-Neuropsychiatric-Disorders.html
https://www.globenewswire.com/news-release/2022/02/01/2376443/0/en/Reviva-Pharmaceuticals-Announces-First-Patients-Dosed-in-Pivotal-Phase-3-Study-and-Long-Term-Safety-Trial-Evaluating-Brilaroxazine-for-the-Treatment-of-Schizophrenia.html
https://www.globenewswire.com/news-release/2022/01/10/2363699/0/en/Reviva-Pharmaceuticals-Holdings-Inc-Receives-FDA-May-Proceed-Letter-for-Pivotal-Phase-3-Clinical-Trial-and-Long-Term-Safety-Trial-Evaluating-Brilaroxazine-For-The-Treatment-of-Schi.html